1.16
price down icon1.69%   -0.02
pre-market  Vorhandelsmarkt:  1.17   0.01   +0.86%
loading
Schlusskurs vom Vortag:
$1.18
Offen:
$1.18
24-Stunden-Volumen:
903.45K
Relative Volume:
0.35
Marktkapitalisierung:
$91.16M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-37.34M
KGV:
-0.8529
EPS:
-1.36
Netto-Cashflow:
$-36.91M
1W Leistung:
-2.52%
1M Leistung:
-8.66%
6M Leistung:
-12.12%
1J Leistung:
-22.15%
1-Tages-Spanne:
Value
$1.13
$1.19
1-Wochen-Bereich:
Value
$1.13
$1.22
52-Wochen-Spanne:
Value
$0.772
$1.84

Sellas Life Sciences Group Inc Stock (SLS) Company Profile

Name
Firmenname
Sellas Life Sciences Group Inc
Name
Telefon
(646) 200-5278
Name
Adresse
7 TIMES SQUARE, NEW YORK, NY
Name
Mitarbeiter
17
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
SLS's Discussions on Twitter

Vergleichen Sie SLS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
SLS
Sellas Life Sciences Group Inc
1.16 91.16M 0 -37.34M -36.91M -1.36
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
502.92 129.14B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
680.61 74.41B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
581.21 35.31B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
241.75 31.30B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
254.57 27.35B 3.32B -860.46M -1.04B -8.32

Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2021-07-21 Eingeleitet Cantor Fitzgerald Overweight
2018-11-01 Eingeleitet Oppenheimer Outperform
2018-04-02 Eingeleitet H.C. Wainwright Buy
2018-03-19 Hochstufung Maxim Group Hold → Buy

Sellas Life Sciences Group Inc Aktie (SLS) Neueste Nachrichten

pulisher
Mar 08, 2025

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Short Interest Update - Defense World

Mar 08, 2025
pulisher
Feb 27, 2025

Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 - The Malaysian Reserve

Feb 27, 2025
pulisher
Feb 26, 2025

SELLAS Life Sciences Group Inc (NASDAQ: SLS) Drops -2.59% In Early Trade; What Lies Ahead? - Stocks Register

Feb 26, 2025
pulisher
Feb 22, 2025

Biotech CEO predicts 'revolutionary' steps toward curing cancer on horizon thanks to AI - AOL

Feb 22, 2025
pulisher
Feb 21, 2025

Sellas reports Phase IIa trial data of SLS009 for DLBCL treatment - Yahoo Finance

Feb 21, 2025
pulisher
Feb 21, 2025

SELLAS Life Sciences Group reports positive results from mid-stage lymphoma treatment trial - MSN

Feb 21, 2025
pulisher
Feb 21, 2025

Promising Outlook for SELLAS Life Sciences: Positive Trial Results and Financial Stability Support ‘Buy’ Rating - TipRanks

Feb 21, 2025
pulisher
Feb 20, 2025

SELLAS reports promising DLBCL treatment trial results By Investing.com - Investing.com Nigeria

Feb 20, 2025
pulisher
Feb 20, 2025

SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL - GlobeNewswire

Feb 20, 2025
pulisher
Feb 20, 2025

3 AI Stocks Lawmakers Are Snapping Up Now - The Globe and Mail

Feb 20, 2025
pulisher
Feb 20, 2025

SELLAS Reports Positive Phase 2a Data For SLS009 With Zanubrutinib In Relapsed/Refractory DLBCL - Nasdaq

Feb 20, 2025
pulisher
Feb 20, 2025

SELLAS reports promising DLBCL treatment trial results - Investing.com

Feb 20, 2025
pulisher
Feb 20, 2025

SELLAS Life Sciences Reports Promising Phase 2a Data for SLS009 in Combination with Zanubrutinib in DLBCL Patients - Nasdaq

Feb 20, 2025
pulisher
Feb 12, 2025

SELLAS Life Sciences Group’s $25 Million Common Stock Offering - Global Legal Chronicle

Feb 12, 2025
pulisher
Feb 10, 2025

SELLAS Life Sciences Group Inc (NASDAQ:SLS) stock crossing the finish line today - US Post News

Feb 10, 2025
pulisher
Feb 10, 2025

Market Insight: SELLAS Life Sciences Group Inc (SLS)’s Notable Drop, Closing at 1.37 - The Dwinnex

Feb 10, 2025
pulisher
Feb 10, 2025

Wall Street analysts’ outlook for SELLAS Life Sciences Group Inc (SLS) - SETE News

Feb 10, 2025
pulisher
Feb 07, 2025

SELLAS Life Sciences Group Sees Unusually High Options Volume (NASDAQ:SLS) - MarketBeat

Feb 07, 2025
pulisher
Feb 06, 2025

SELLAS Life Sciences Group Inc (NASDAQ: SLS) Stock Has Gained 38.89% Over The Month – Is There Room For Growth? – Marketing Sentinel - Marketing Sentinel

Feb 06, 2025
pulisher
Feb 06, 2025

Orangekloud Technology Inc (NASDAQ: ORKT) Up 58.11% From 52-Week Low; YTD Falls -50.99% – Here’s What To Do Now – Marketing Sentinel - Marketing Sentinel

Feb 06, 2025
pulisher
Feb 06, 2025

Stock Traders Buy Large Volume of Call Options on SELLAS Life Sciences Group (NASDAQ:SLS) - MarketBeat

Feb 06, 2025
pulisher
Feb 05, 2025

Insider’s View: Deciphering SELLAS Life Sciences Group Inc (SLS)’s Financial Health Through Ratios - The Dwinnex

Feb 05, 2025
pulisher
Feb 04, 2025

Market Analysts see SELLAS Life Sciences Group Inc [SLS] gaining to $18. Time to buy? - The DBT News

Feb 04, 2025
pulisher
Feb 04, 2025

SELLAS Life Sciences Group Target of Unusually Large Options Trading (NASDAQ:SLS) - Defense World

Feb 04, 2025
pulisher
Feb 03, 2025

You Should Read This Analysis Before Investing in SELLAS Life Sciences Group Inc (NASDAQ:SLS) - US Post News

Feb 03, 2025
pulisher
Jan 31, 2025

Sellas Life Sciences Group Announces $25 Million Registered Direct Offering - Defense World

Jan 31, 2025
pulisher
Jan 30, 2025

Analysts Provide An Important Insights On SELLAS Life Sciences Group Inc (SLS) - Stocks Register

Jan 30, 2025
pulisher
Jan 29, 2025

SEC Form 424B5 filed by SELLAS Life Sciences Group Inc. - Quantisnow

Jan 29, 2025
pulisher
Jan 28, 2025

SELLAS secures $25 million in registered direct offering By Investing.com - Investing.com South Africa

Jan 28, 2025
pulisher
Jan 28, 2025

SELLAS secures $25 million in registered direct offering - MSN

Jan 28, 2025
pulisher
Jan 28, 2025

SELLAS Life Sciences Group Announces $25 Million Registered - GlobeNewswire

Jan 28, 2025
pulisher
Jan 28, 2025

Major Healthcare Investor Backs SELLAS with $25M DealHere's the Full Structure - StockTitan

Jan 28, 2025
pulisher
Jan 24, 2025

SELLAS Life Sciences Group Sees Unusually Large Options Volume (NASDAQ:SLS) - Defense World

Jan 24, 2025
pulisher
Jan 23, 2025

SELLAS Life Sciences Announces Positive Phase 3 Trial Results - TipRanks

Jan 23, 2025
pulisher
Jan 23, 2025

SELLAS Life Sciences stock falls on GPS data (SLS:NASDAQ) - Seeking Alpha

Jan 23, 2025
pulisher
Jan 23, 2025

SELLAS Life Sciences Announces Positive Outcome of Interim - GlobeNewswire

Jan 23, 2025
pulisher
Jan 23, 2025

SELLAS Phase 3 AML Trial Shows Promising 13.5-Month Survival Data, Double Historical Average - StockTitan

Jan 23, 2025
pulisher
Jan 23, 2025

Biotech CEO predicts 'revolutionary decade' in medicine through AI advancements - Fox News

Jan 23, 2025
pulisher
Jan 22, 2025

SLS Stock Quote Price and Forecast - CNN

Jan 22, 2025
pulisher
Jan 18, 2025

SELLAS Life Sciences amends executive severance agreements - MSN

Jan 18, 2025
pulisher
Jan 17, 2025

SELLAS Life Sciences Group Inc (NASDAQ: SLS): Blank Check On Growth? - Stocks Register

Jan 17, 2025
pulisher
Jan 17, 2025

SELLAS Life Sciences Group Approves Amendments to Change in Control Severance Agreements - Defense World

Jan 17, 2025
pulisher
Jan 17, 2025

SELLAS Life Sciences amends executive severance agreements By Investing.com - Investing.com Australia

Jan 17, 2025
pulisher
Jan 16, 2025

SELLAS Life Sciences Amends Severance for Key Executives - TipRanks

Jan 16, 2025

Finanzdaten der Sellas Life Sciences Group Inc-Aktie (SLS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$75.07
price up icon 1.39%
$305.39
price down icon 0.55%
$19.19
price down icon 3.62%
$32.68
price down icon 0.52%
$97.47
price down icon 2.84%
biotechnology ONC
$254.57
price up icon 1.89%
Kapitalisierung:     |  Volumen (24h):